Hepatic cholesterol homeostasis: Is the low-density lipoprotein pathway a regulatory or a shunt pathway?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 11, 2013, Pages 2481-2490

  Sniderman, Allan D ^a   Qi, Yanqin ^a   Ma, Cheng I J ^a   Wang, Rui Hao Leo ^a   Naples, Mark ^b,c   Baker, Chris ^b,c   Zhang, Jing ^b,c   Adeli, Khosrow ^b,c   Kiss, Robert S ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A; cholesterol; high density lipoproteins; very?low density lipoproteins

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE 1; CHOLESTEROL ACYLTRANSFERASE 2; CHYLOMICRON REMNANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; CHOLESTEROL ESTERIFICATION; CHOLESTEROL LIVER LEVEL; CHOLESTEROL SYNTHESIS; FLUORESCENCE MICROSCOPY; HAMSTER; HOMEOSTASIS; LIVER CELL; NONHUMAN; PRIORITY JOURNAL;

3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; CHOLESTEROL; HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS;

ANIMALS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CHYLOMICRONS; CRICETINAE; FIBROBLASTS; HEPATOCYTES; HOMEOSTASIS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIPID METABOLISM; RECEPTORS, LDL;

EID: 84887030875     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301517     Document Type: Article

References (41)

1. Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholes-terolemia. N Engl J Med. 1983;309:288-296.
2. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
3. Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab. 2008;8:512-521.
4. Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res. 2009;50(Suppl):S15-S27.
5. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29:431-438.
6. Lange Y, Ory DS, Ye J, Lanier MH, Hsu FF, Steck TL. Effectors of rapid homeostatic responses of endoplasmic reticulum cholesterol and 3-hydroxy-3-methylglutaryl-CoA reductase. J Biol Chem. 2008;283:1445-1455.
7. Lange Y, Steck TL, Ye J, Lanier MH, Molugu V, Ory D. Regulation of fbroblast mitochondrial 27-hydroxycholesterol production by active plasma membrane cholesterol. J Lipid Res. 2009;50:1881-1888.
8. Sniderman AD, Zhang Z, Genest J, Cianfone K. Effects on apoB-100 secretion and bile acid synthesis by redirecting cholesterol effux from HepG2 cells. J Lipid Res. 2003;44:527-532.
9. Zhang Z, Cianfone K, Sniderman AD. Role of cholesterol ester mass in regulation of secretion of ApoB100 lipoprotein particles by hamster hepa-tocytes and effects of statins on that relationship. Arterioscler Thromb Vasc Biol. 1999;19:743-752.
10. Pangburn SH, Newton RS, Chang CM, Weinstein DB, Steinberg D. Receptor-mediated catabolism of homologous low density lipoproteins in cultured pig hepatocytes. J Biol Chem. 1981;256:3340-3347.
11. Havekes LM, Verboom H, de Wit E, Yap SH, Princen HM. Regulation of low density lipoprotein receptor activity in primary cultures of human hepatocytes by serum lipoproteins. Hepatology. 1986;6:1356-1360.
12. Cohen LH, Princen HM, Kwekkeboom J, Havekes LM, Kempen HJ. Regulation of cholesterol metabolism in the liver in vivo and in vitro. Biochem Soc Trans. 1987;15:339-340.
13. Havekes LM, de Wit EC, Princen HM. Cellular free cholesterol in Hep G2 cells is only partially available for down-regulation of low-density-lipoprotein receptor activity. Biochem J. 1987;247:739-746.
14. Wu GY, Wu CH, Rifci VA, Stockert RJ. Activity and regulation of low density lipoprotein receptors in a human hepatoblastoma cell line. Hepatology. 1984;4:1190-1194.
15. Harders-Spengel K, Wood CB, Thompson GR, Myant NB, Soutar AK. Difference in saturable binding of low density lipoprotein to liver membranes from normocholesterolemic subjects and patients with heterozygous familial hypercholesterolemia. Proc Natl Acad Sci USA. 1982;79:6355-6359.
16. Dueland S, Trawick JD, Nenseter MS, MacPhee AA, Davis RA. Expression of 7 alpha-hydroxylase in non-hepatic cells results in liver phenotypic resistance of the low density lipoprotein receptor to cholesterol repression. J Biol Chem. 1992;267:22695-22698.
17. Ye ZJ, Go GW, Singh R, Liu W, Keramati AR, Mani A. LRP6 protein regulates low density lipoprotein (LDL) receptor-mediated LDL uptake. J Biol Chem. 2012;287:1335-1344.
18. Truong TQ, Auger A, Denizeau F, Brissette L. Analysis of low-density lipoprotein catabolism by primary cultures of hepatic cells from normal and low-density lipoprotein receptor knockout mice. Biochim Biophys Acta. 2000;1484:307-315.
19. Strong A, Ding Q, Edmondson AC, Millar JS, Sachs K V, Li X, et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catab-olism. J Clin Invest. 2012;122:2807-2816.
20. Sniderman AD, Kiss RS. The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis. Curr Atheroscler Rep. 2007;9:261-265.
21. Lange Y, Steck TL. Cholesterol-rich intracellular membranes: a precursor to the plasma membrane. J Biol Chem. 1985;260:15592-15597.
22. Brown MS, Dana SE, Goldstein JL. Receptor-dependent hydrolysis of cholesteryl esters contained in plasma low density lipoprotein. Proc Natl Acad Sci USA. 1975;72:2925-2929.
23. Myers JN, Tabas I, Jones NL, Maxfeld FR. Beta-very low density lipo-protein is sequestered in surface-connected tubules in mouse peritoneal macrophages. J Cell Biol. 1993;123(6 Pt 1):1389-1402.
24. Tabas I, Myers JN, Innerarity TL, Xu XX, Arnold K, Boyles J, et al. The infuence of particle size and multiple apoprotein E-receptor interactions on the endocytic targeting of beta-VLDL in mouse peritoneal macro-phages. J Cell Biol. 1991;115:1547-1560.
25. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J Lipid Res. 2012;53:2515-2524.
26. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 2013;127:2403-2413.
27. Xu W, Liu L, Hornby D. c-IAP1 binds and processes PCSK9 protein: linking the c-IAP1 in a TNF-α pathway to PCSK9-mediated LDLR degradation pathway. Molecules. 2012;17:12086-12101.
28. Benjannet S, Saavedra YG, Hamelin J, Asselin MC, Essalmani R, Pasquato A, et al. Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem. 2010;285:40965-40978.
29. Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipopro-tein receptor. Arterioscler Thromb Vasc Biol. 2012;32:1585-1595.
30. Wu M, Dong B, Cao A, Li H, Liu J. Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters. Atherosclerosis. 2012;224:401-410.
31. Li H, Liu J. The novel function of HINFP as a co-activator in ste-rol-regulated transcription of PCSK9 in HepG2 cells. Biochem J. 2012;443:757-768.
32. Cao A, Wu M, Li H, Liu J. Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J Lipid Res. 2011;52:518-530.
33. Sorrentino V, Zelcer N. Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor. Curr Opin Lipidol. 2012;23:213-219.
34. Zhang L, Reue K, Fong LG, Young SG, Tontonoz P. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. Arterioscler Thromb Vasc Biol. 2012;32:2541-2546.
35. Ishibashi M, Masson D, Westerterp M, Wang N, Sayers S, Li R, et al. Reduced VLDL clearance in Apoe(-/-)Npc1(-/-) mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels. J Lipid Res. 2010;51:2655-2663.
36. Dong B, Wu M, Cao A, Li H, Liu J. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression. Int J Mol Med. 2011;27:103-110.
37. Brown MS, Goldstein JL. Analysis of a mutant strain of human fbroblasts with a defect in the internalization of receptor-bound low density lipopro-tein. Cell. 1976;9(4 Pt 2):663-674.
38. Lange Y, Steck TL. Quantitation of the pool of cholesterol associated with acyl-CoA:cholesterol acyltransferase in human fbroblasts. J Biol Chem. 1997;272:13103-13108.
39. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, Witztum JL, et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 2009;119:3236-3245.
40. Kiss RS, You Z, Genest J Jr, Behm DJ, Giaid A. Urotensin II differentially regulates macrophage and hepatic cholesterol homeostasis. Peptides. 2011;32:956-963.
41. Khelef N, Buton X, Beatini N, Wang H, Meiner V, Chang TY, et al. Immunolocalization of acyl-coenzyme A:cholesterol O-acyltransferase in macrophages. J Biol Chem. 1998;273:11218-11224.